To take the orally disintegrating tablet (Zofran ODT): In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), do not exceed a total daily dose of 8 mg [see Use in Specific Populations
Adults and children 12 years of age and older—At first, 8 milligrams (mg) taken 30 minutes before starting cancer treatment
Alternatively, 4-8 mg intermittent short-term IV dosing used in adults; single dose of 4 mg single dose used in pregnancy Uremic Pruritus (Off-label) 8 mg divided q12hr or 8 mg q8-12hr PO for See full prescribing information for the recommended dosage in adults and pediatrics
Highlights for ondansetron Ondansetron orally disintegrating tablet is available as a brand-name drug and as a generic drug
Each 8-mg ZOFRAN ODT Orally Disintegrating Tablet for oral administration contains 8 mg ondansetron base
Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer
Ondansetron has excellent utility as an antiemetic drug, and it is effective against nausea
(2
risk of QT prolongation, cardiac arrhythmias (additive effects) citalopram
Then, the dose is 8 mg every 8 hours